Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States

2023/07/20 by James D. Lewis, Lauren E. Parlett, Michele L. Jonsson Funk +15 · 30 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Inflammatory Bowel Disease #Pregnancy and Medication Impact #Rheumatoid Arthritis Research and Therapies

paper · pdf · doi:10.1053/j.gastro.2023.07.003

Cited by

• Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis
• Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn’s Disease: 2025 AGA Evidence Synthesis
• Regional specialization within the mammalian respiratory immune system
• Trends in Mortality Due to Inflammatory Bowel Disease in the United States: A CDC WONDER Database Analysis (1999–2020)
• Epithelia mediate inflammation with myeloid cells in Crohn’s disease patients under treatment
• NOD-like Receptor Signaling Pathway in Gastrointestinal Inflammatory Diseases and Cancers. [europepmc]
• Intestinal strictures in Crohn's disease: An update from 2023. [europepmc]
• Differential Manifestations of Inflammatory Bowel Disease Based on Race and Immigration Status. [europepmc]
• Natural approaches for the management of ulcerative colitis: evidence of preclinical and clinical investigations. [europepmc]
• Consensus Statement on Managing Anxiety and Depression in Individuals with Inflammatory Bowel Disease. [europepmc]
• ACSL4 mediates inflammatory bowel disease and contributes to LPS-induced intestinal epithelial cell dysfunction by activating ferroptosis and inflammation. [europepmc]
• High-Salt Diet and Intestinal Microbiota: Influence on Cardiovascular Disease and Inflammatory Bowel Disease. [europepmc]
• Inflammation and aging-related disease: A transdisciplinary inflammaging framework. [europepmc]
• Healthcare Access for Patients With Inflammatory Bowel Disease in the United States: A Survey by the Crohn's & Colitis Foundation. [europepmc]
• Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. [europepmc]
• Regional specialization within the mammalian respiratory immune system. [europepmc]
• AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. [europepmc]
• Oral Pathogens' Substantial Burden on Cancer, Cardiovascular Diseases, Alzheimer's, Diabetes, and Other Systemic Diseases: A Public Health Crisis-A Comprehensive Review. [europepmc]
• Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. [europepmc]
• Altered inflammatory mucosal signatures within their spatial and cellular context during active ileal Crohn's disease. [europepmc]
• Advances in gut microbiota functions in inflammatory bowel disease: Dysbiosis, management, cytotoxicity assessment, and therapeutic perspectives. [europepmc]
• Engineered Probiotic Saccharomyces boulardii Reduces Colitis-Associated Colorectal Cancer Burden in Mice. [europepmc]
• Balance between bile acid conjugation and hydrolysis activity can alter outcomes of gut inflammation. [europepmc]
• IFN-γ-Induced intestinal epithelial cell-type-specific programmed cell death: PANoptosis and its modulation in Crohn's disease. [europepmc]
• Global evolution of inflammatory bowel disease across epidemiologic stages. [europepmc]
• Intestinal organoids in inflammatory bowel disease: advances, applications, and future directions. [europepmc]
• Current and forecasted 10-year prevalence and incidence of inflammatory bowel disease in Hong Kong, Japan, and the United States. [europepmc]
• Single-cell and spatial transcriptomics of stricturing Crohn's disease highlights a fibrosis-associated network. [europepmc]
• Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. [europepmc]
• Microfluidics-enabled polydopamine-coated selenium nanoparticles in hyaluronic hydrogel microspheres for targeted antioxidant and immunomodulatory therapy of ulcerative colitis. [europepmc]